Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Buy
85
OZEM Quote, Financials, Valuation and Earnings
Last price:
$26.63
Seasonality move
:
15.06%
Day range:
$27.03 - $27.49
52-week range:
$20.01 - $29.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.8K
Avg. volume:
11.9K
1-year change:
3.67%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$27.13 | -- | -- | -- | $0.05 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$31.97 | -- | -- | -- | $0.15 | 0.78% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$24.84 | -- | -- | -- | $0.12 | 1.93% | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
$28.81 | -- | -- | -- | $0.47 | 0.5% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.39 | -- | -- | -- | $0.04 | 1.13% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$23.55 | -- | -- | -- | $0.22 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.655 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.597 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 0.835 | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | 0.636 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 0.658 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.815 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
Roundhill GLP-1 & Weight Loss ETF vs. Competitors
-
Which has Higher Returns OZEM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About OZEM or AGNG?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Global X Aging Population ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is OZEM or AGNG More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.366%.
-
Which is a Better Dividend Stock OZEM or AGNG?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.05 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.78% to investors and pays a quarterly dividend of $0.15 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or AGNG?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns OZEM or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is OZEM or FTXH More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.143%.
-
Which is a Better Dividend Stock OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.05 per share corresponding to a yield of 0%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.93% to investors and pays a quarterly dividend of $0.12 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns OZEM or HRTS?
Tema GLP-1, Obesity & Cardiometabolic ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Tema GLP-1, Obesity & Cardiometabolic ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- -
What do Analysts Say About OZEM or HRTS?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema GLP-1, Obesity & Cardiometabolic ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Tema GLP-1, Obesity & Cardiometabolic ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Tema GLP-1, Obesity & Cardiometabolic ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 HRTSTema GLP-1, Obesity & Cardiometabolic ETF0 0 0 -
Is OZEM or HRTS More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema GLP-1, Obesity & Cardiometabolic ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or HRTS?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.05 per share corresponding to a yield of 0%. Tema GLP-1, Obesity & Cardiometabolic ETF offers a yield of 0.5% to investors and pays a quarterly dividend of $0.47 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Tema GLP-1, Obesity & Cardiometabolic ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or HRTS?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Tema GLP-1, Obesity & Cardiometabolic ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Tema GLP-1, Obesity & Cardiometabolic ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Tema GLP-1, Obesity & Cardiometabolic ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Tema GLP-1, Obesity & Cardiometabolic ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- HRTSTema GLP-1, Obesity & Cardiometabolic ETF-- -- -- --
-
Which has Higher Returns OZEM or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is OZEM or IBBQ More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.05 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.13% to investors and pays a quarterly dividend of $0.04 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns OZEM or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is OZEM or THNR More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.05 per share corresponding to a yield of 0%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.22 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 16
VEON [VEON] is up 4.61% over the past day.
Buy
74
DAVE alert for Jun 16
Dave [DAVE] is up 3.92% over the past day.
Buy
54
DAR alert for Jun 16
Darling Ingredients [DAR] is up 7.19% over the past day.
